Jazz Pharmaceuticals (JAZZ) director sells 6,000 shares under plan

Rhea-AI Filing Summary

Jazz Pharmaceuticals director Bruce C. Cozadd sold 6,000 Ordinary Shares on August 3, 2026 at $252.98 per share in a sale described as an open market or private transaction. The sale occurred automatically under a Rule 10b5-1 trading plan adopted on November 26, 2025, and does not represent a discretionary trade. Following this transaction, he directly holds 360,682 shares of Jazz Pharmaceuticals.

Insider Trade Summary 10b5-1

Net Seller: 6,000 shares

Net Sell 1 txn

Insider COZADD BRUCE C

Role Director

Sold 6,000 shs ($1.52M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1	6,000	$252.98	$1.52M

Holdings After Transaction: Ordinary Shares — 360,682 shares (Direct)

Footnotes (1)

1. F1. This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Key Figures

Shares sold: 6,000 shares Sale price: $252.98 per share Shares held after sale: 360,682 shares

3 metrics

Shares sold 6,000 shares Ordinary Shares sold on August 3, 2026

Sale price $252.98 per share Price for Ordinary Shares sold on August 3, 2026

Shares held after sale 360,682 shares Direct holdings following the August 3, 2026 transaction

Key Terms

Rule 10b5-1, Securities Exchange Act of 1934, open market or private transaction

3 terms

Rule 10b5-1 regulatory

"plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Securities Exchange Act of 1934 regulatory

"in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended"

open market or private transaction market

"transaction code description: Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 04:33 PM Accepted by SEC EDGAR 08/05/2026 - 04:33 PM Learn about SEC filing dates

FAQ

What insider transaction did Jazz Pharmaceuticals (JAZZ) report?

Jazz Pharmaceuticals reported that director Bruce C. Cozadd sold 6,000 Ordinary Shares on August 3, 2026. The sale was an open-market or private transaction executed automatically under a Rule 10b5-1 trading plan adopted on November 26, 2025.

At what price did Bruce Cozadd sell Jazz Pharmaceuticals (JAZZ) shares?

Bruce C. Cozadd sold Jazz Pharmaceuticals shares at $252.98 per share. The transaction involved 6,000 Ordinary Shares on August 3, 2026 and was carried out automatically under a pre-established Rule 10b5-1 trading plan.

How many Jazz Pharmaceuticals (JAZZ) shares does Bruce Cozadd hold after this sale?

After the reported sale, Bruce C. Cozadd directly holds 360,682 Jazz Pharmaceuticals Ordinary Shares. This figure reflects his direct ownership position immediately following the August 3, 2026 transaction disclosed in the insider report.

Was the Jazz Pharmaceuticals (JAZZ) share sale made under a Rule 10b5-1 plan?

Yes. The filing states the sale was made under a Rule 10b5-1 trading plan adopted on November 26, 2025. The transaction occurred automatically and is described as not representing a discretionary trade by the reporting person.

What is Bruce Cozadd’s role at Jazz Pharmaceuticals (JAZZ) in this insider filing?

Bruce C. Cozadd is identified as a director of Jazz Pharmaceuticals. The Form 4 reports his direct ownership and the sale of 6,000 Ordinary Shares executed under a Rule 10b5-1 trading plan on August 3, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COZADD BRUCE C

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City) (State) (Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/03/2026		S(1)		6,000	D	$252.98	360,682	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

	By: /s/Paz Dizon, as attorney in fact For: Bruce C. Cozadd	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)